NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 69 filers reported holding NURIX THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $36,321 | +9.3% | 4,621 | +39.0% | 0.00% | 0.0% |
| Q2 2023 | $33,217 | +12.5% | 3,325 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $29,526 | -29.8% | 3,325 | 0.0% | 0.00% | -50.0% |
| Q4 2022 | $42,061 | -2.2% | 3,325 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $43,000 | +2.4% | 3,325 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $42,000 | +23.5% | 3,325 | +35.4% | 0.00% | +100.0% |
| Q1 2022 | $34,000 | -52.1% | 2,456 | 0.0% | 0.00% | -50.0% |
| Q4 2021 | $71,000 | -4.1% | 2,456 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $74,000 | +13.8% | 2,456 | 0.0% | 0.00% | +50.0% |
| Q2 2021 | $65,000 | +6.6% | 2,456 | +26.1% | 0.00% | 0.0% |
| Q1 2021 | $61,000 | +96.8% | 1,947 | +105.8% | 0.00% | +100.0% |
| Q4 2020 | $31,000 | -6.1% | 946 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $33,000 | – | 946 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |